{
    "nct_id": "NCT04685811",
    "official_title": "Evaluation of a 68Ga Small Molecule PSMA Antagonist Produced by Two Different Methods",
    "inclusion_criteria": "Subjects must meet all of the following criteria to be enrolled in this study:\n\n* Aged 21 years or older and below 80 years of age\n* Signed written informed consent and willingness to comply with protocol requirements\n* Histologically confirmed diagnosis of metastatic prostate cancer\n* Staging imaging exam confirming metastatic disease, e.g. total body MRI, or CT chest/abdomen/pelvis, 99mTc bone scan, NaF PET\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 21 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "* Laboratory values:\n* Serum creatinine >2.5 mg/dL\n* AST (SGOT) >2.5x ULN\n* Bilirubin (total) >1.5x ULN\n* Serum calcium >11 mg/dL\n* Presence of any other co-existing condition which, in the judgment of the investigator, might increase the risk to the subject.\n* Presence of serious systemic illness, including: uncontrolled inter-current infection, uncontrolled malignancy, significant renal disease, or psychiatric/social situations, which might limit compliance with study requirements.\n* Other severe acute or chronic medical condition(s) or laboratory abnormality(ies) that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and in the judgment of the investigator, would make the patient inappropriate for entry into this study.\n* Inability to lay on the scanner table for the required period of time, e.g., due to bone pain or claustrophobia.",
    "miscellaneous_criteria": ""
}